Featured Publications
Larynx Cancer
Fan D, Kang J, Yu Y, Cahlon O, Riaz N, Lee N. Larynx Cancer. Practical Guides In Radiation Oncology 2022, 45-60. DOI: 10.1007/978-3-030-99590-4_4.Peer-Reviewed Original ResearchPostoperative radiotherapyLarynx cancerEarly stage squamous cell carcinomaOrgan preservation therapyEarly-stage diseaseLymph node metastasisAdvanced larynx cancerSquamous cell carcinomaStandard of careHigh-risk casesPre-treatment evaluationCommon clinical scenariosThin-cut CTPET/CTDefinitive chemoradiotherapyAdvanced diseaseLocoregional recurrencePreservation therapyGlottic larynxNode metastasisSubglottic extensionCell carcinomaLaryngeal cancerPhysical examOrgan preservation
2024
Outcomes of Reduced Elective Nodal Radiation Dose for Laryngeal, Hypopharyngeal and p16 Negative Oropharyngeal Cancers
Zakeri K, Shang T, Yu Y, Chen L, Shamseddine A, Kang J, Tsai C, Sherman E, Wong R, McBride S, Gelblum D, Riaz N, Lee N. Outcomes of Reduced Elective Nodal Radiation Dose for Laryngeal, Hypopharyngeal and p16 Negative Oropharyngeal Cancers. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e807. DOI: 10.1016/j.ijrobp.2024.07.1772.Peer-Reviewed Original ResearchP16-negative oropharyngeal squamous cell carcinomaNegative oropharyngeal squamous cell carcinomasOropharyngeal squamous cell carcinomaDistant recurrenceSquamous cell carcinomaNodal recurrenceRadiotherapy doseLocoregional recurrenceP16 statusCell carcinomaHypopharynx cancerP16-negative oropharyngeal cancerHead and neck cancer patientsRadiation doseElective nodal volumesP16-negative diseaseNode-positive diseaseDecrease treatment toxicityNeck cancer patientsPrimary outcome measureConcurrent cetuximabConcurrent chemotherapyLocoregional controlMedian followNodal disease
2023
Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer
Han J, Zakeri K, Raab G, Hesse J, Shamseddine A, Chen L, Yu Y, Kang J, McBride S, Riaz N, Tsai C, Gelblum D, Sherman E, Wong R, Michel L, Lee N. Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer. Head & Neck 2023, 45: 2207-2216. PMID: 37439286, PMCID: PMC10981461, DOI: 10.1002/hed.27456.Peer-Reviewed Original ResearchConceptsLocoregional recurrenceDistant metastasisOverall survivalHNSCC patientsConcurrent carboplatinDefinitive chemoradiationConsecutive HNSCC patientsDefinitive radiation therapyMedian radiation doseKaplan-Meier methodCumulative incidence functionFree survivalAdvanced headMedian ageMedian dosesNeck cancerAUC 1Radiation therapyCarboplatinPatientsChemoradiationPaclitaxelRadiation doseExcellent optionIncidence function
2022
Physician Graded Toxicity Profiles and Survival Outcomes among Patients with Non-Metastatic Oropharyngeal Carcinoma Treated with Proton Therapy vs. Intensity-Modulated Radiation Therapy
Youssef I, Yoon J, Zakeri K, Cohen M, Wong R, Yu Y, Kang J, Gelblum D, McBride S, Sherman E, Dunn L, Cracchiolo J, Chen L, Lee N. Physician Graded Toxicity Profiles and Survival Outcomes among Patients with Non-Metastatic Oropharyngeal Carcinoma Treated with Proton Therapy vs. Intensity-Modulated Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e325-e326. DOI: 10.1016/j.ijrobp.2022.07.1399.Peer-Reviewed Original ResearchProgression-free survivalIntensity-modulated radiation therapyOropharyngeal carcinomaAcute gradeIMRT groupLocoregional recurrenceOncologic outcomesAdverse eventsOverall survivalRadiation therapyPT groupSignificant differencesTreatment-related adverse eventsPatient/tumor characteristicsProton therapyCurative-intent radiationGrade 3 dysphagiaPresence of xerostomiaMedian RT doseRetrospective cohort studyProspective Randomized ComparisonPatient-reported outcomesSimilar oncologic outcomesMATERIAL/METHODSReduction of dose
2021
TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence
Yu Y, Fan D, Song X, Zakeri K, Chen L, Kang J, McBride S, Tsai CJ, Dunn L, Sherman E, Katabi N, Dogan S, Cracchiolo J, Cohen M, Boyle JO, Lee M, Valero C, Wang J, Wong R, Morris L, Riaz N, Lee N. TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence. JCO Precision Oncology 2021, 5: 1259-1269. PMID: 34381934, PMCID: PMC8345918, DOI: 10.1200/po.20.00515.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaLocoregional failurePatterns of failureCumulative incidenceCell carcinomaPromoter mutationsHPV-positive oropharyngeal squamous cell carcinomaMemorial Sloan-Kettering Cancer CenterRisk of LRFOropharyngeal squamous cell carcinomaNeck squamous cell carcinomaHPV-negative HNSCCsReverse transcriptase (TERT) promoter mutationsOral cavity cancerNext-generation sequencingTERT promoter mutationsDisease subsiteLocoregional recurrenceOverall cohortOverall survivalProspective cohortCancer CenterHuman papillomavirusLaryngopharyngeal cancerUnique pathogenesis